Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares gained nearly 3% in premarket trading on Monday after the company reported fourth-quarter results that topped analyst expectations and issued 2026 revenue guidance above consensus forecasts.
The biopharmaceutical company posted adjusted earnings per share of $0.06 for the fourth quarter, exceeding analyst estimates of $0.02 by $0.04.
Quarterly revenue came in at $85.81 million, beating the consensus forecast of $81.38 million and marking a 42.8% increase from $60.10 million in the same quarter last year. For full-year 2025, total revenue rose 43.7% year over year to $291.85 million, compared with $203.07 million in 2024.
Xeris projected full-year 2026 revenue in the range of $375 million to $390 million. The midpoint of $382.5 million stands roughly 4% above analyst consensus estimates of $368 million. The company also expects adjusted EBITDA to increase in absolute terms compared with 2025, although research and development expenses are expected to rise by approximately $25 million as it launches a Phase 3 trial for XP-8121. Selling, general and administrative costs are also projected to increase by about $45 million, largely driven by continued investment in Recorlev.
“2025 was a transformational year, marked by focused execution, record revenue growth, and our emergence as a self-funding, sustainable biopharmaceutical company,” said Chief Executive Officer John Shannon.
Recorlev net revenue doubled year over year, rising 100.5% to $45.33 million in the fourth quarter, supported by growing patient demand. Gvoke net revenue increased 5.9% to $24.65 million due to improved net pricing, while Keveyis net revenue advanced 15.1% to $12.80 million, also driven by higher patient demand.
For the full year 2025, Xeris reported net income of $0.55 million, compared with a net loss of $54.84 million in 2024. Adjusted EBITDA reached $59.42 million for the year, representing an improvement of $58.2 million from the prior period.